Treatments for non-small-cell lung cancer [ID6234]

Suggested remit: To appraise the clinical and cost effectiveness of treatments for non-small-cell lung cancer.

Status:

Discontinued

Technology type:

Medicine

Decision:

Selected

Reason for decision:

Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources

Rationale:

Scoping commencing

Process:

Pathways Pilot

ID number:

6234

Project Team

Project lead

Celia Mayers

Email enquiries

If you have any queries please email TATeam6@nice.org.uk

External Assessment Group:

Bristol Technology Assessment Group, University of Bristol

Stakeholders

Others

Department of Health and Social Care

 

NHS England

Patient carer groups

ALK Positive UK

 

EGFR Positive UK

 

Roy Castle Lung Cancer Foundation

Professional groups

Association of Cancer Physicians

 

British Thoracic Oncology Group

 

British Thoracic Society

 

Cancer Research UK

 

Royal College of Physicians

 

Royal College of Radiologists

Comparator companies

Pathway companies:

 

AbbVie

 

Amarox (erlotinib) – confidentiality agreement not signed, not participating

 

AstraZeneca (durvalumab, osimertinib)

 

Boehringer Ingelheim (afatinib) – confidentiality agreement not signed, not participating

 

Cipla EU (gefitinib) – confidentiality agreement not signed, not participating

 

Daiichi Sankyo (trastuzumab deruxtecan)

 

GlaxoSmithKline

 

Johnson & Johnson Innovative Medicine (amivantamab)

 

Merck (tepotinib)

 

Novartis (ceritinib, dabrafenib, trametinib)

 

Pfizer (crizotinib, dacomitinib, lorlatinib) – confidentiality agreement not signed, not participating

 

Regeneron (cemiplimab) – confidentiality agreement not signed, not participating

 

Roche (alectinib)

 

Takeda (brigatinib)

 

Comparator companies:

 

Amgen (sotorasib)

 

Aspire Pharma (pemetrexed) – confidentiality agreement not signed, not participating

 

Bayer (laroctrectinib)

 

Boehringer Ingelheim (nintedanib) – confidentiality agreement not signed, not participating

 

Bristol Myers Squibb (nivolumab, paclitaxel)

 

Celltrion Healthcare UK (bevacizumab) – confidentiality agreement not signed, not participating

 

Dr Reddy’s Laboratories (pemetrexed) – confidentiality agreement not signed, not participating

 

Eli Lilly (selpercatinib, pemetrexed)

 

Genus Pharmaceuticals (pemetrexed) – confidentiality agreement not signed, not participating

 

Hospira UK (cisplatin, carboplatin, oxaliplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed) – confidentiality agreement not signed, not participating

 

Inceptua (paclitaxel) – confidentiality agreement not signed, not participating

 

Medac (oxaliplatin, vinorelbine) – confidentiality agreement not signed, not participating

 

Merck Sharp & Dohme UK (pembrolizumab)

 

Mylan (pemetrexed) – confidentiality agreement not signed, not participating

 

Organon Pharma (bevacizumab) – confidentiality agreement not signed, not participating

 

Pfizer (pemetrexed, bevacizumab) – confidentiality agreement not signed, not participating

 

Pierre Fabre (vinorelbine) – confidentiality agreement not signed, not participating

 

Roche (atezolizumab, bevacizumab entrectinib)

 

Sandoz (cisplatin, pemetrexed) – confidentiality agreement not signed, not participating

 

Sanofi

 

Seacross Pharmaceuticals (oxaliplatin, docetaxel, paclitaxel) – confidentiality agreement not signed, not participating

 

Takeda (mobocertinib)

 

Thornton and Ross (bevacizumab) – confidentiality agreement not signed, not participating

 

Zentiva (bevacizumab) – confidentiality agreement not signed, not participating

General commentators

All Wales Therapeutics and Toxicology Centre

 

British National Formulary

 

Department of Health, Social Services and Public Safety for Northern Ireland

 

Healthcare Improvement Scotland

 

Medicines and Healthcare products Regulatory Agency

 

Scottish Medicines Consortium

 

Welsh Government

Relevant research groups

Institute of Cancer Research

Timeline

Key events during the development of the guidance:

For further information on our processes and methods, please see our CHTE processes and methods manual